Navigation Links
Cequent Names F. Stephen Laroux, Ph.D., Director, Immunology and Inflammatory Diseases
Date:6/2/2009

CAMBRIDGE, Mass., June 2 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has promoted F. Stephen Laroux, Ph.D., to the new position of director, immunology and inflammatory diseases, effective immediately. Dr. Laroux joined the company as a scientist in 2007. Today, he leads the team of Cequent researchers developing drug candidates using Cequent's proprietary tkRNAi delivery platform against a series of targets thought to be important in gastro-intestinal diseases, such as inflammatory bowel disease (IBD). Dr. Laroux's current study portfolio includes the target associated with Cequent's partnership with Novartis, as well as Cequent's in-house IBD program.

"While we are furthest along with our drug candidate CEQ508, an orally administered tkRNAi therapeutic targeting the primary oncogene (beta-catenin, CTNNB1) in FAP (familial adenomatous polyposis) -- our IBD program is actually the company's largest, and Stephen has been critical to our rapid progress over the past 18 months," said Cequent President and CEO, Peter Parker. "We started with fourteen potential therapeutic targets for IBD, including several in our partnership with Novartis. We have finished in vivo testing on candidate treatments against our first four targets, and all have exhibited significant efficacy. This is a testament to the promise of our tkRNAi technology -- but also to Stephen's skills and tenacity in both study design and execution. Thanks to his leadership and hard work we are now positioned to file two IND (investigational new drug) applications with the FDA for IBD therapeutics next year."

Dr. Laroux completed a post-doctoral fellowship at Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School where he conducted research focused on innate immune responses to bacteria a
'/>"/>

SOURCE Cequent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cequent Names Ted Hibben Chief Business Officer
2. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
6. AIAA names top ten emerging aerospace technologies of 2009
7. Microbia, Inc. Names Alex Chu as Vice President of Process Development
8. Premier Research Names Hal Ward, R.Ph., PharmD as Executive Director, Global Pharmacovigilance
9. Pulmonary Hypertension Association Names Dr. Nicholas Hill Recipient of 2009 Award of Excellence in Pulmonary Arterial Hypertension (PAH) Care
10. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
11. Hospira Names Brian Meadows Supply Chain Chief
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... today in the journal PNAS (Proceedings of the ... of day and sleep deprivation have a significant effect ... looking at the best time of day to test ... for administering medicines effectively. , Researchers from the University ... investigated the links between sleep deprivation, body clock disruption ...
(Date:7/10/2014)... and spiders can sit upside down forever. Nanophysics makes sure ... in an article just published in Physical Review E ... Geckos and spiders that seem to be able to sit ... worldwide for many years. We will soon be able to ... the gecko,s foot. But the fact is, sooner or later ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
(Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2
... The U.S. Food and Drug,Administration (FDA) has ... treatment for complicated intra-abdominal and complicated urinary,tract ... a wide range of Gram-positive(1) and Gram-negative(2),bacteria ... serious infections. DORIBAX belongs to a ...
... Oct. 15 It is with great privilege ... of John A.,Elefteriades, M.D., F.A.C.S. to its Board ... W.L. Glenn Professor of Cardiothoracic,Surgery and Chief of ... He serves as Co-Director of the Yale-New Haven ...
... ADELAIDE, Australia, Oct. 15 Ellex Medical Lasers,Limited ... and manufacture of,ophthalmic laser and ultrasound systems, announced ... McGuinness to its board of directors to,underpin the ... and a capital raising in the past twelve ...
Cached Biology Technology:FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 2FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 3FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 4FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections 5Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors 2John Marshall and Kevin McGuinness Appointed to Ellex Board 2
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
(Date:7/10/2014)... July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication ... Mr. Gino Pereira was interviewed on July 1 ... Tampa Florida . Mr. Pereira discusses the company,s ... Harris and how the Wocket™ aims to replace a ... Cedric Harris tells Gino he has never ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new ... (DW). An Asian OEM has selected FPC1021 for a flagship ... August 2014.   FPC is proud to announce ... planned date for start of mass production in August 2014. ... 5M, for delivery in the first half of July. The ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... test could alter the screening landscape for colorectal cancer, ... Cancer Research special conference on Colorectal Cancer: Biology to ... cancer is the third leading cause of cancer, and ... continue to undergo public colonoscopies in an effort to ...
... October 28, 2010 For Immediate Release A ... the Scripps Translational Science Institute has published a paper ... genetic variations that reveal whether people are predisposed to ... In our modern genetic age, the entire DNA sequences, ...
... team of scientists at the Institut de recherches cliniques ... of the Cytoskeletal Organization and Cell Migration research unit, ... cell motility. Their findings were published online today in ... Press group. This scientific breakthrough could eventually lead to ...
Cached Biology News:New test measures DNA methylation levels to predict colon cancer 2Scientists describe new approach for identifying genetic markers for common diseases 2Scientists describe new approach for identifying genetic markers for common diseases 3A recent IRCM breakthrough impacts cancer research 2
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
... The versatile Promega Flipper® Racks are ... of your small tubes. These polypropylene racks ... choice for freezer storage. They may also ... Each rack is two-sided; one side accommodates ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
...
Biology Products: